18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial
- PMID: 24224999
- DOI: 10.1016/S0140-6736(13)61754-7
18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial
Abstract
Background: The use of non-invasive imaging to identify ruptured or high-risk coronary atherosclerotic plaques would represent a major clinical advance for prevention and treatment of coronary artery disease. We used combined PET and CT to identify ruptured and high-risk atherosclerotic plaques using the radioactive tracers (18)F-sodium fluoride ((18)F-NaF) and (18)F-fluorodeoxyglucose ((18)F-FDG).
Methods: In this prospective clinical trial, patients with myocardial infarction (n=40) and stable angina (n=40) underwent (18)F-NaF and (18)F-FDG PET-CT, and invasive coronary angiography. (18)F-NaF uptake was compared with histology in carotid endarterectomy specimens from patients with symptomatic carotid disease, and with intravascular ultrasound in patients with stable angina. The primary endpoint was the comparison of (18)F-fluoride tissue-to-background ratios of culprit and non-culprit coronary plaques of patients with acute myocardial infarction.
Findings: In 37 (93%) patients with myocardial infarction, the highest coronary (18)F-NaF uptake was seen in the culprit plaque (median maximum tissue-to-background ratio: culprit 1·66 [IQR 1·40-2·25] vs highest non-culprit 1·24 [1·06-1·38], p<0·0001). By contrast, coronary (18)F-FDG uptake was commonly obscured by myocardial uptake and where discernible, there were no differences between culprit and non-culprit plaques (1·71 [1·40-2·13] vs 1·58 [1·28-2·01], p=0·34). Marked (18)F-NaF uptake occurred at the site of all carotid plaque ruptures and was associated with histological evidence of active calcification, macrophage infiltration, apoptosis, and necrosis. 18 (45%) patients with stable angina had plaques with focal (18)F-NaF uptake (maximum tissue-to-background ratio 1·90 [IQR 1·61-2·17]) that were associated with more high-risk features on intravascular ultrasound than those without uptake: positive remodelling (remodelling index 1·12 [1·09-1·19] vs 1·01 [0·94-1·06]; p=0·0004), microcalcification (73% vs 21%, p=0·002), and necrotic core (25% [21-29] vs 18% [14-22], p=0·001).
Interpretation: (18)F-NaF PET-CT is the first non-invasive imaging method to identify and localise ruptured and high-risk coronary plaque. Future studies are needed to establish whether this method can improve the management and treatment of patients with coronary artery disease.
Funding: Chief Scientist Office Scotland and British Heart Foundation.
Copyright © 2014 Joshi et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.
Comment in
-
A new frontier in atherosclerotic coronary imaging.Lancet. 2014 Feb 22;383(9918):674-5. doi: 10.1016/S0140-6736(13)61911-X. Epub 2013 Nov 11. Lancet. 2014. PMID: 24225000 No abstract available.
-
[¹⁸F-NaF PET-CT: a new method for imaging of ruptured and rupture-endangered atherosclerotic plaques].Radiologe. 2014 Sep;54(9):856-8. doi: 10.1007/s00117-014-2724-5. Radiologe. 2014. PMID: 25106465 German. No abstract available.
-
Novel imaging techniques to identify unstable arteriosclerotic plaques.Vasa. 2017 May;46(3):232. doi: 10.1024/0301-1526/a000615. Vasa. 2017. PMID: 28466776 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
- PG/09/083/27667/BHF_/British Heart Foundation/United Kingdom
- FS/11/14/28692/BHF_/British Heart Foundation/United Kingdom
- FS/10/024/28266/BHF_/British Heart Foundation/United Kingdom
- FS/13/77/30488/BHF_/British Heart Foundation/United Kingdom
- FS/10/026/28209/BHF_/British Heart Foundation/United Kingdom
- FS/14/78/31020/BHF_/British Heart Foundation/United Kingdom
- FS/12/29/29463/BHF_/British Heart Foundation/United Kingdom
- G0701127/MRC_/Medical Research Council/United Kingdom
- ETM/160/CSO_/Chief Scientist Office/United Kingdom
- PG/12/8/29371/BHF_/British Heart Foundation/United Kingdom
- FS/10/026/BHF_/British Heart Foundation/United Kingdom
- CH/09/002/BHF_/British Heart Foundation/United Kingdom
- FS/10/024/BHF_/British Heart Foundation/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical